「fortherepublic of kiribati」の検索結果
135件：56～60件目を表示
-
General Announcement: May 9, 2024 Senju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion S...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509_0.pdf -
TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and licensed to Senju as...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
General Announcement: May 9, 2024 Senju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion S...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509.pdf -
TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Mr. Naoyuki Mochida; hereinafter: Mochida) and licensed to Senju as...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
千寿製薬株式会社
NEWS & RELEASE April 6, 2026 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF） December 22, 2025 Obtained manufacturing a...
http://www.senju.co.jp/english/